The company is reportedly considering splitting its biopharmaceuticals arm, which markets its multiple sclerosis drug Tysabri, from EDT. According to the publication, Elan could boost the value of its biopharmaceuticals business by rolling off its debt of over $1 billion into the EDT unit.